Orforglipron
Checked Oct 11, 2026 · 18 sources checked
Orforglipron is a once-daily pill that activates the GLP-1 receptor, the same target as semaglutide. The FDA's approval announcement calls it a partial agonist. It is a small chemical rather than a protein-like peptide, so it can be swallowed as a pill. Eli Lilly makes it. The FDA approved it as Foundayo on April 1 2026. It is approved, alongside diet and exercise, to help adults with obesity lose excess weight and keep it off. The approval also covers adults with overweight plus a weight-related condition. In the US it is a prescription medicine. Phase 3 trials have also tested it in type 2 diabetes, including against oral semaglutide. A placebo-controlled trial of its effect on heart attacks and strokes is enrolling.
Education only, not medical advice. Talk to a clinician about your own situation.
Attention is moderate and steady. English Wikipedia's Orforglipron article had 7,360, 8,594 and 8,695 views in July, August and September 2026. PubMed added 12 records in the 30 days to Oct 11 2026, against about 10.3 a month in the preceding 90 days (31 records). NBC News covered the FDA approval on 2026-04-01. That is a past event, not current heat, so we use no "getting hot" label.
In adults with obesity and no diabetes, daily orforglipron reduced body weight by 7.5% to 11.2% on average across the three doses tested over 72 weeks, versus 2.1% with placebo. Side effects led 5.3% to 10.3% of people on orforglipron to stop, versus 2.7% on placebo.
For adults with established atherosclerotic cardiovascular disease and/or chronic kidney disease, does orforglipron reduce heart attacks, strokes and cardiovascular deaths compared with placebo?
If NCT07241390 shows a reduction in major cardiovascular events versus placebo, we would add cardiovascular benefit for that population to "What we know". A null result would mean its cardiovascular case rests on safety only.
A pooled analysis of seven phase 3 trials (11,220 participants) found no case meeting drug-induced liver injury criteria (PMID 42338042). If longer follow-up or later safety analyses show a new serious-harm signal, we would add it to "What we know".
Word on the street
Who's covering it lately. Coverage means people are talking about it; it isn't evidence, and it never changes our read.
- Reuters · Sep 29, 2026Read the coverage ↗
- The Wall Street Journal · Aug 25, 2026Read the coverage ↗
- The Guardian · Aug 24, 2026Read the coverage ↗
- BBC · Aug 10, 2026Read the coverage ↗
For the pros: claims, studies and receipts18 sources · tap to open
6 reviewed claim records · 18 linked source receipts Inspect source receipts
Maturity: source checked
In adults with obesity and no diabetes, daily orforglipron reduced body weight by 7.5% to 11.2% on average across the three doses tested over 72 weeks, versus 2.1% with placebo. Side effects led 5.3% to 10.3% of people on orforglipron to stop, versus 2.7% on placebo.
Adults with obesity (or overweight with complications), without diabetes · Outcome: Percent change in body weightConfidence applies to this claim and context.
Identity
Metabolic / obesity · active ingredient
Identity checked Oct 7, 2026. This establishes the catalog name; evidence assessment is separate.
Checked facts
- In adults with obesity and no diabetes, daily orforglipron reduced body weight by 7.5% to 11.2% on average across the three doses tested over 72 weeks, versus 2.1% with placebo. Side effects led 5.3% to 10.3% of people on orforglipron to stop, versus 2.7% on placebo. PMID 40960239 ↗
- After weight loss on tirzepatide or semaglutide, people switched to orforglipron kept more of that weight loss at 52 weeks than people switched to placebo: 74.7% vs 49.2% in the tirzepatide cohort and 79.3% vs 37.6% in the semaglutide cohort. The trial had no group that stayed on injections, and it lasted 52 weeks. NCT NCT06584916 ↗
- In adults with early type 2 diabetes managed with diet and exercise, orforglipron lowered HbA1c by 0.83 to 1.07 percentage points more than placebo over 40 weeks; stopping because of side effects was 4.4-7.8% vs 1.4%. PMID 40544435 ↗
- In adults with obesity or overweight and type 2 diabetes, orforglipron reduced body weight by 5.1% to 9.6% on average across doses over 72 weeks, versus 2.5% with placebo. PMID 41275875 ↗
- In adults with type 2 diabetes on metformin, orforglipron lowered HbA1c more than oral semaglutide over 52 weeks. It also caused more gastrointestinal side effects, more discontinuations for side effects and a larger rise in pulse rate. PMID 41765029 ↗
- In people with type 2 diabetes at increased cardiovascular risk, orforglipron was non-inferior to insulin glargine for major cardiovascular events (4.2% vs 5.0%; hazard ratio 0.84, 95% CI 0.59-1.20) over a median of 2 years. This is a safety comparison, not proof of cardiovascular benefit. PMID 42815506 ↗
Attention describes reviewed public attention, evidence shows study types, and confidence applies only to the stated claim. There is no overall score.
Claims
Would change this claim: If NCT07241390 shows a reduction in major cardiovascular events versus placebo, we would add cardiovascular benefit for that population to "What we know". A null result would mean its cardiovascular case rests on safety only.
Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. · PMID 40960239 · The New England journal of medicine · Abstract, Results: -7.5%, -8.4%, -11.2% vs -2.1%; AE discontinuation 5.3-10.3% vs 2.7% · Verify ↗Source: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities · NCT NCT05869903 · Eli Lilly and Company · Abstract, Results: -7.5%, -8.4%, -11.2% vs -2.1%; AE discontinuation 5.3-10.3% vs 2.7% · Verify ↗Mapped studies / experiment families
One experiment counts once, even with several registrations or publications. Counts above describe the headline claim.
No reviewed experiment families mapped yet.
Studies & active trials
Only papers and registered trials an editor reviewed for this page. Being listed is not a finding; the claims above say what they show.
What still isn't settled?
For adults with established atherosclerotic cardiovascular disease and/or chronic kidney disease, does orforglipron reduce heart attacks, strokes and cardiovascular deaths compared with placebo?
Its only completed cardiovascular trial compared it with insulin glargine in type 2 diabetes. That trial was designed to show safety (non-inferiority), and its confidence interval (0.59-1.20) cannot exclude no effect.
What would answer it: The primary result of NCT07241390, a placebo-controlled event-driven phase 3 trial in about 7,140 adults with established ASCVD and/or CKD (estimated primary completion 2031-08), on major adverse cardiovascular events.
Already settled: weight loss versus placebo over 72 weeks in adults with obesity without diabetes (ATTAIN-1, NEJM 2025).
Prioritize the next check →